Heart transplant patients with hypertrophic cardiomyopathy have high survival rates

Transplant surgery to correct the most common type of genetic heart disease yields similar short-term and potentially greater long-term survival rates as transplant surgery for other heart diseases, according to research reported in Circulation: Heart Failure, an American Heart Association journal.

Researchers found similar survival rates one year after heart transplant surgery between hypertrophic cardiomyopathy (HCM) patients (85 percent) and those with other kinds of heart disease (82 percent). Five years post-surgery, survival rates began to diverge with 75 percent of HCM and 70 percent of other patients surviving. At the 10-year mark, survival rates in both groups dropped, although they remained significantly higher in the HCM patients (61 percent) than in those with other heart diseases (49 percent).

“Patients with this disease who are undergoing transplant can expect reasonable long-term survival rates," said Martin S. Maron, M.D., lead author and assistant professor of medicine, director of the Hypertrophic Cardiomyopathy Center, and co-director of Advanced Cardiac Imaging at Tufts Medical Center in Boston, Mass. “That’s a crucial clinical message for this small but important subgroup of patients."

Investigators used the United Network of Organ Sharing Registry, a nationwide database of all U.S. transplant patients, to analyze 26,706 adult patients’ clinical and survival characteristics. HCM patients comprise about 1 percent of all U.S. heart transplant cases. Yet, the survival rate is comparable to surgeries for other reasons.

Study participants were mostly white (81 percent) and male (79 percent), average age 52. HCM patients, however, tended to be younger, average age 43, and more than half were women. Nearly one-third (31 percent) of participants reported smoking, although this rate was much lower among those with HCM (17 percent). All had received a heart transplant between January 1990 and December 2004.

Co-authors are Benjamin M. Kalsmith, M.D.; James E. Udelson, M.D.; Wenjun Li, Ph.D. and David DeNofrio, M.D.


DOLについて - 利用規約 -  会員規約 -  著作権 - サイトポリシー - 免責条項 - お問い合わせ
Copyright 2000-2025 by HESCO International, Ltd.